Granted Patent B2

US 12,553,083 · App. 17/018,831 · Granted Feb 17, 2026

Inventors: Allison Ryan (Belmont, CA); Styrmir Sigurjonsson (San Jose, CA); Milena Banjevic (Los Altos Hills, CA); George Gemelos (Portland, OR); Matthew Hill (Belmont, CA); Johan Baner (San Francisco, CA); Matthew Rabinowitz (San Francisco, CA); Zachary Demko (San Francisco, CA)

Assignee: Natera, Inc.

C12Q1/6869C12Q1/6844C12Q1/6876G16B10/00C12Q2600/156

Abstract

Claims (25)

1 . A method of processing a nucleic acid sample useful for cancer monitoring, the method comprising:

(a) obtaining a nucleic acid sample comprising cell-free DNA from the blood of a patient;

(b) isolating the cell-free DNA from the nucleic acid sample;

(c) generating a barcoded sequencing library by tagging the isolated cell-free DNA with a plurality of barcodes;

(d) enriching the barcoded sequencing library by adding a plurality of hybrid capture probes to the barcoded sequencing library, hybridizing the plurality of hybrid capture probes to a corresponding plurality of targets in the barcoded sequencing library to form a plurality of probe-target duplexes, and isolating the plurality of probe-target duplexes;

(e) obtaining a plurality of sequence reads via high-throughput sequencing of the enriched barcoded sequencing library; and

wherein the sequence reads comprise a single nucleotide polymorphism (SNP), a duplication, an insertion, a deletion, an inversion, and/or a combination thereof.

2 . The method of claim 1 , wherein the high-throughput sequencing in (e) comprises: pooling the enriched barcoded sequencing library with one or more additional sequencing libraries obtained from biological samples from other patients, wherein the enriched barcoded sequencing library and the one or more additional sequencing libraries are each tagged with distinct barcode sequences; and sequencing the pooled libraries.

3 . The method of claim 2 , wherein the patient has cancer or is suspected of having cancer, and wherein the cell-free DNA comprises a mix of healthy cell-free DNA and tumor-derived cell-free DNA.

4 . The method of claim 2 , wherein each hybrid capture probe comprises a probe sequence designed to be at least partially complementary to one or more target sequences of the corresponding plurality of targets.

5 . The method of claim 4 , wherein the probe sequence comprises a biotinylated nucleic acid.

6 . The method of claim 5 , wherein isolating the probe-target duplexes in (d) comprises physically removing the probe-target duplexes using a solid support with streptavidin affixed.

7 . The method of claim 6 , wherein the solid support is a magnetic bead.

8 . The method of claim 2 , wherein the plurality of targets comprises greater than 50 targets.

9 . The method of claim 2 , wherein the isolated cell-free DNA from (b) comprises between 1 ng and 100 ng of cell-free DNA.

10 . The method of claim 2 , further comprising tagging the isolated cell-free DNA with sequencing adaptors for high-throughput sequencing.

11 . The method of claim 2 , wherein tagging in (c) comprises ligation of the molecular barcodes to the isolated cell-free DNA.

12 . The method of claim 11 , wherein ligation comprises blunt-end ligation or sticky-end ligation.

13 . The method of claim 2 , further comprising, prior to (e): selectively enriching the barcoded sequencing library by targeted amplification of a plurality of target sequences of the tagged cell-free DNA.

14 . The method of claim 2 , wherein the plurality of barcodes comprises at least two distinct barcodes.

15 . The method of claim 2 , wherein the hybrid capture probes comprise PCR primers.

16 . The method of claim 1 , further comprising reducing a level of error in the sequence reads by attaching a probability to a sequence read comprising a SNP.

17 . The method of claim 16 , wherein the level of error is determined using a maximum likelihood technique.

18 . The method of claim 16 , wherein reducing the level of error comprises comparing a plurality of predefined regions in the sequence reads to a reference distribution of genotypes.

19 . The method of claim 1 , further comprising: determining a percentage of sequences having the SNP, a duplication, an insertion, a deletion, an inversion, and/or a combination thereof.

Assignments (2)

Continuity (12)

References Cited (400)